Table 1.

Headache relief after intravenous and oral lasmiditan, subcutaneous and oral sumatriptan, and oral LY334370 in randomised, clinical trials (RCTs) [7, 15, 17, 20]

Drug	Headache relief for active drug at 2 h (%)	Headache relief for placebo at 2 h (%)	Therapeutic gain (95 % confidence intervals) (%)	NNT (number needed to treat)
Intravenous lasmiditan 20 mg [15]	64	45	19 (−4 to 42 %)a	5.3
Oral lasmiditan 400 mg [17]	64	25	38 (28 to 51 %)	2.6
Subcutaneous sumatriptan 6 mg [7]	69	19	51 (48 to 53 %)	2.0
Oral sumatriptan 100 mg [7]	61	28	33 (31 to 35 %)	3.0
LY334370 200 mg [20]	71	19	52 (27 to 77 %)	2.0

^aThe RCT did not have the power to compare the single doses of lasmiditan with placebo